来自:中国糖尿病杂志 编辑:潘长玉|点击数:|2016-03-03
【提要】 我国成年糖尿病前期患病人群庞大,且以IGT患者为主。IGT不仅是T2DM的高危因素,还与糖尿病微血管并发症及大血管并发症密切相关。干预IGT,阻止或延缓其发展为糖尿病已成为当务之急。当单纯生活方式干预无法达到预期的糖尿病预防目标时,应考虑采用药物进行治疗。本文将对IGT的病理生理机制、IGT药物干预的有效性、安全性及药物经济学作一综述。
【关键词】 糖耐量减低;生活方式干预;药物干预
Pharmacological Intervention of IGT
【Summary】There is a huge population of adults with pre-diabetes in China,and the majority of whom are impaired glucose tolerance(IGT) patients. IGT is not only a risk factor for type2
diabetes,but is also closely related to diabetic microvascular and macrovascular complications. Preventing or delaying the development of diabetes by intervention on IGT has become imperative.When lifestyle intervention alone cannot achieve the ideal goal of diabetes prevention, pharmacological intervention should be considered. This review will discuss thepathophysiology of IGT,
and the effectiveness, safety and pharmacoeconomics of IGT pharmacological intervention.
【Key words】 Impaired glucose tolerance(IGT); Lifestyle intervention; Pharmacological
intervention
版权所有:《中国糖尿病杂志》社 主管单位:中华人民共和国教育部 主办单位:北京大学
地址:北京市西城区大红罗厂街1号 邮编:100034 电话(传真):010-88505683
中国糖尿病杂志社版权所 京ICP备11029051号-1 Powered by JiuduCMS 技术支持:九度创想